scholarly journals Biological markers of Barrett’s esophagus progression to adenocarcinoma

2020 ◽  
Vol 174 (5) ◽  
pp. 91-98
Author(s):  
T. A. Karmakova ◽  
S. S. Pirogov ◽  
A. D. Kaprin

Barrett’s esophagus (BE) is a condition in which a stratifi ed squamous epithelium of the distal esophagus is replaced with a metaplastic intestinal-type columnar epithelium. BE is a precancerous condition associated with an increased risk of esophageal adenocarcinoma (EA). Current clinical practice guidelines recommend endoscopic surveillance with histological examination of esophageal biopsies for early detection of the EA. Epithelial dysplasia is the only clinically meaningful indicator of the risk for development carcinoma in BE, which is now used in practice. The existing limitations of this approach require new tools for the detection of early neoplastic disorders in BE and additional criteria to assess a risk for their progression. Within the framework of this review, the most signifi cant genetic and molecular indicators that can claim the role of diagnostic or predictive biological markers in BE are considered.

2021 ◽  
Author(s):  
Luka Vranić ◽  
Tin Nadarević ◽  
Davor Štimac

Background: Barrett’s esophagus (BE) requires surveillance to identify potential neoplasia at early stage. Standard surveillance regimen includes random four-quadrant biopsies by Seattle protocol. Main limitations of random biopsies are high risk of sampling error, difficulties in histology interpretation, common inadequate classification of pathohistological changes, increased risk of bleeding and time necessary to acquire the final diagnosis. Probe-based confocal laser endomicroscopy (pCLE) has emerged as a potential tool with an aim to overcome these obvious limitations. Summary: pCLE represents real-time microscopic imaging method that offers evaluation of epithelial and subepithelial structures with 1000-fold magnification. In theory, pCLE has potential to eliminate the need for biopsy in BE patient. The main advantages would be real-time diagnosis and decision making, greater diagnostic accuracy and to evaluate larger area compared to random biopsies. Clinical pCLE studies in esophagus show high diagnostic accuracy and its high negative predictive value offers high reliability and confidence to exclude dysplastic and neoplastic lesions. However, it still cannot replace histopathology due to lower positive predictive value and sensitivity. Key messages: Despite promising results, its role in routine use in patients with Barrett’s esophagus remains questionable primarily due to lack of well-organized double-blind randomized trials.


2019 ◽  
Vol 18 (3) ◽  
pp. 425-429 ◽  
Author(s):  
Rita M. Knotts ◽  
Quinn S. Solfisburg ◽  
Claire Keating ◽  
Emily DiMango ◽  
Charles J. Lightdale ◽  
...  

2013 ◽  
Vol 58 (11) ◽  
pp. 3178-3188 ◽  
Author(s):  
Katherine S. Garman ◽  
Kouros Owzar ◽  
Elizabeth R. Hauser ◽  
Kristen Westfall ◽  
Blair R. Anderson ◽  
...  

Author(s):  
K Y Song ◽  
A J Henn ◽  
A A Gravely ◽  
H Mesa ◽  
S Sultan ◽  
...  

SUMMARY Patients with Barrett's esophagus (BE) and low-grade dysplasia (LGD) are at increased risk of esophageal adenocarcinoma (EAC), although many regress to nondysplastic BE. This has significant clinical importance for patients being considered for endoscopic eradication therapy. Our aim is to determine the risk for progression in patients with confirmed persistent LGD. We performed a single-center retrospective cohort study of patients with BE and confirmed LGD between 2006 and 2016. Confirmed LGD was defined as LGD diagnosed by consensus conference with an expert GI pathologist or review by an expert GI pathologist and persistence as LGD present on subsequent endoscopic biopsy. The primary outcome was the incidence rate of HGD (high-grade dysplasia)/EAC. Secondary outcomes included risk factors for dysplastic progression. Risk factors for progression were assessed using univariate and multivariate analysis with logistic regression. Of 69 patients (mean age 65.2 years) with confirmed LGD were included. In total, 16 of 69 patients (23.2%) with LGD developed HGD/EAC during a median follow-up of 3.74 years (IQR, 1.24–5.45). For persistent confirmed LGD, the rate was 6.44 (95% confidence interval (CI), 2.61–13.40) compared to 2.61 cases per 100 patient-years (95% CI, 0.83–6.30) for nonpersistent LGD. Persistent LGD was found in only 29% of patients. Persistent LGD was an independent risk factor for the development of HGD/EAC (OR 4.18; [95% CI, 1.03–17.1]). Persistent confirmed LGD, present in only 1/3 of patients, was an independent risk factor for the development of HGD/EAC. Persistence LGD may be useful in decision making regarding the management of BE.


2018 ◽  
Vol 1 ◽  
pp. 5-5
Author(s):  
Martin Riegler ◽  
Gerd Jomrich ◽  
Sebastian F. Schoppmann

2020 ◽  
Vol 158 (6) ◽  
pp. S-318-S-319
Author(s):  
Ahmad Alkaddour ◽  
Muhammad Talal Sarmini ◽  
Mohammad Maysara Asfari ◽  
Kenneth J. Vega

Sign in / Sign up

Export Citation Format

Share Document